ScholarWorks@Korea University College of Medicine: Shin, Sang Won

Detailed Information

Shin, Sang Won (신상원)

Anam Hospital (Department of Medical Oncology and Hematology, Anam Hospital)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

테스트:15||chemotherapy:7||Korea:7||a:6||Chemotherapy:5||Cisplatin:5||cisplatin:5||Nonsmallcell lung carcinoma:4||UFT:3||epirubicin:3||EGFR mutation:3||leucovorin:3||Docetaxel:3||cancer:2||Adjuvant chemotherapy:2||Retinoic acid:2||Cauda equina syndrome:2||UFTE:2||lung cancer:2||Rituximab chemotherapy:2||combination chemotherapy:2||BRCA2:2||Gefitinib:2||KRAS:2||Primary adrenal lymphoma:2||Korean:2||overall survival:2||advanced gastric carcinoma:2||paclitaxel:2||Prognosis:2||peripheral blood stem cell transplantation:2||anemia:2||5fluorouracil:2||gastric carcinoma:2||prognostic model:2||FCSGE:2||120170:2||BRCA1:2||Febrile neutropenia:2||Chest xray:1||Children and adolescents:1||Cisplatin failure:1||Clonality:1||Clostridium difficile:1||Colonic neoplasms:1||Colorectal neoplasms:1||Combination chemotherapy:1||Concomitant chemoradiation:1||Continuity of patient care:1||Drug therapy:1||Drugresistant cancer cell lines:1||EGFR:1||ERCC1:1||ERK phosphorylation:1||ESAS:1||Edmonton Symptom Assessment System:1||Endoflife care:1||Epidermal growth factor receptor:1||Epidermal growth factor receptor mutation:1||Epirubicin:1||EpsteinBarr virus:1||Erlotinib:1||Esophageal squamous cell carcinoma:1||Etoposide:1||FOLFIRI:1||FOLFOX:1||Field cancerization:1||Foxp3(+) Treg:1||GMCSF:1||Gastric Bypass:1||Gastric adenocarcinoma:1||Gemcitabine:1||Haplotypes:1||Head and neck neoplasms:1||Hematologic malignancy:1||Hepatocellular neoplasm:1||Heptaplatin:1||High blood pressure:1||Highthroughput nucleotide sequencing:1||Humans:1||Ifosfamide:1||Irinotecan:1||Janus kinase 3:1||Kras:1||KRAS mutation:1||Korean population:1||Lazertinib:1||Leucovorin:1||Loss of Heterozygosity:1||Loss of heterozygosity:1||Lung:1||Lung adenocarcinoma:1||Lung cancer:1||Lung neoplasms:1||Lymphoma:1||MVAC protocol:1||MDAMB231:1||Malignancy:1||Meat consumption:1||Medical oncologists:1||Metabolic tumor volume:1||Metastatic breast cancer:1||Metastatic burden:1||Metastatic cancer:1||Molecular:1||Mutations:1||NF kappa B:1||NK/Tcell lymphoma:1||NO donor:1||NSCLC:1||Nail change:1||Nasopharyngeal cancer:1||Nasopharyngeal carcinoma:1||Nausea:1||Neoplasm:1||Neuropathic pain:1||Neutropenia:1||NonHodgkin's lymphoma:1||Nonsmall cell lung cancer:1||Nonsmallcell lung cancer:1||Obesity:1||Obesity, Morbid:1||Ondansetron:1||Oral etoposide:1||Ovarian neoplasms:1||Overall survival:1||Pain management:1||Pancreas neoplasm:1||Pancreatic adenocarcinoma:1||Pathology:1||Pemetrexed:1||Physician orders for lifesustaining treatment:1||Polymorphism:1||Precision medicine:1||Prognostic factors:1||Prognostic model:1||Quality of life:1||RASSF1A:1||RET:1||RTPCR:1||Ramosetron:1||Refractory:1||Reninangiotensin system:1||Retrospective analysis:1||SLE:1||Second primary cancer:1||Secondline:1||Secondline chemotherapy:1||Sensitive:1||Serum DNA:1||Serum and tumor samples:1||Single nucleotide polymorphisms of the TGFB1 gene and lung cancer risk in a korean population:1||Small cell lung cancer:1||Small cell lung carcinoma:1||Solid cancer:1||Squamous cell carcinoma of the head and neck:1||Stage:1||Stomach neoplasm:1||Tcell nonHodgkin lymphoma:1||Targetable gene alteration:1||Total lesion glycolysis:1||Transcatheter arterial chemoembolization:1||Treatment outcome:1||Tyrosine kinase inhibitors:1||University students:1||Urothelial carcinoma:1||VEGF/VEGFR2 growth pathway, autocrine:1||Varicella zoster virus:1||Vascular endothelial growth factor:1||Vomiting:1||Weekly docetaxel:1||Weight Loss:1||advanced non small cell lung cancer:1||analgesics:1||biliary tract carcinoma:1||body mass:1||body weight loss:1||braest cancer sporadic:1||breast cancer:1||burden:1||cerbB2 protooncogene:1||capecitabine:1||cellfree DNA:1||cellfree DNA concentration:1||cholangiocarcinoma:1||chronic neutrophilic leukemia:1||colon cancer:1||colorectal cancer:1||custom panel:1||cyclooxygenase2 inhibitor:1||cyclooxygenase2independent target:1||differentiation:1||docetaxel:1||dump freezing:1||early breast cancer:1||elderly:1||embryoid body:1||embryonic stem cells:1||family caregiver:1||febrile neutropenia:1||gastric bypass surgery:1||gemcitabine:1||haplotypes:1||head and neck cancer:1||hepatocellular carcinoma:1||hepatocellular carcinoma (HCC):1||highdose immune globulin:1||human:1||human immunodeficiency virus:1||hypoxia:1||iNOS:1||idiopathic thrombocytopenic purpura (ITP):1||ifosfamide:1||imatinib mesylate:1||laminar air flow:1||longterm engraftment stability:1||lymphoma, nonHodgkin:1||lymphopenia:1||metastatic breast cancer:1||mitomycin:1||morbid obesity:1||more than thirdline:1||mutations:1||nonsmallcell lung cancer:1||p53:1||peripheral blood:1||pharmacogenomics:1||platelet count:1||polymorphism:1||precision medicine:1||prevalence:1||prognosis:1||prognosis factor:1||prognostic value:1||quality of life:1||radiosensitizer:1||recurrence:1||refractory colon cancer:1||retinoic acid:1||salvage therapy:1||secondline chemotherapy:1||sequencing:1||serum and tumor samples:1||splenectomy:1||stomach neoplasms:1||t(15:1||targeted sequencing:1||taxane resistant:1||uPAR:1||uracil and tegafur (UFT):1||uracil plus tegafur (UFT):1||vascular endothelial growth factor:1||vinorelbine:1||급속냉각법:1||말초혈 조혈모세포이식:1||방사선 화학 동시요법:1||비소세포폐암:1||소세포폐암:1||전신방사선조사:1||조혈모세포이식:1||피부근염:1||80 degrees C freezer:1||혈관염:1||19):1||5FU:1||ACEI/ARB:1||ADI:1||Adenocarcinoma:1||Adriamycin:1||Advance directives:1||Advanced cancer:1||Aged:1||Albumin:1||Allogeneic hematopoietic stem cell transplantation:1||Alternative medicine:1||Anthracycline:1||AntiEGFR:1||Aprepitant:1||Attitude:1||BRCA1 gene:1||BclXL:1||Beau's line:1||Bicarbonate:1||Biliary tract cancer:1||Body Mass Index:1||Bone morphogenetic protein2:1||Breast cancer:1||Breast cancer sporadic:1||Breast neoplasms:1||Bronchioloalveolar carcinoma:1||Creactive protein:1||CD8(+) T cell:1||CEA:1||COVID19:1||CXCR4:1||Cancer:1||Cancer pain survey:1||Cancer perception:1||Carcinoma:1||Cellfree nucleic acids quantification:1||Chemotherapy, second line:1||

STATISTICS: Total View :12,652,497; Today View :6,393

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE